The Texas A&m University System

Board of Trustees of the University of Arkansas

University of Guelph

United States of America, As Represented by the Secretary of Agriculture

John R Barta

Billy M Hargis

Luc Berghman

Lisa Bielke

Olivia B Faulkner

Srichaitanya Shivaramaiah

Sherryll Layton

Young Min Kwon

Walter G Bottje

Kimberly Cole

Mandy Cox

Guillermo Tellez

Walter Bottje

Saeed El-Ashram

Harry D Danforth

Said El-Ashram

M Aggie Fernando

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

Compositions and methods of enhancing immune responses toor limitinginfection

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Vaccines comprising TRAP polypeptides andvectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.

Compositions and methods of enhancing immune responses to

[object Object]

Compositions and methods of enhancing immune responses to Eimeria

Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or morality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.

An immunovariant strain ofwas isolated. Vaccines incorporating the immunovariant strain are effective in eliciting immunological protection against coccidial infection.

Growing community of inventors

Guelph, Canada

John R Barta